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ABSTRACT
Purpose Bacterial superinfections, including pneumonia, are frequent complications of inﬂuenza-like illness (ILI). Clinical and laboratory
evidence suggests that benzodiazepines and Z-drugs may inﬂuence susceptibility to infections and mortality. We investigated whether ben-
zodiazepines and zopiclone modify the occurrence of ILI-related pneumonia and mortality.
Methods We obtained data on 804 051 ILI patients from a comprehensive primary care database, the Clinical Practice Research Datalink.
The follow-up period started from the diagnosis of ILI for 30 days. Pneumonia and deaths occurring within the 30-day follow-up period were
considered as potentially ‘ILI related’. Exposure to benzodiazepines and zopiclone was determined in the period preceding a diagnosis of ILI
with current use deﬁned as a prescription for benzodiazepines in the month prior to ILI diagnosis. Cox regression was used for the analyses.
Adjusted hazard ratios (HRs) with 95% conﬁdence intervals (CIs) are presented.
Results Inﬂuenza-like illness-related pneumonia and mortality were noted in 1117 and 707 ILI patients, respectively. Current exposure to
benzodiazepines was associated with increased occurrence of both ILI-related pneumonia and mortality (ILI-related pneumonia adjusted HR
4.24, 95%CI [2.27, 7.95]; ILI-related mortality adjusted HR 20.69, 95%CI [15.54, 27.54]). A similar increase in ILI-related mortality but not
pneumonia was observed with current zopiclone use (ILI-related mortality adjusted HR 10.86, 95%CI [6.93, 17.02]; ILI-related pneumonia
adjusted HR 1.97, 95%CI [0.63, 6.12]).
Conclusion Benzodiazepines may increase the likelihood of pneumonia and mortality related to ILI. A cautionary approach to prescribing
benzodiazepine is suggested in people known to be at increased risk of pneumonia or mortality. Copyright © 2016 John Wiley & Sons, Ltd.
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INTRODUCTION
Inﬂuenza-like illness (ILI) is a common diagnosis in
primary care and exerts considerable morbidity and
mortality worldwide. In the UK, in a typical winter,
primary care consultations for inﬂuenza and ILI rise
from a baseline of less than 30 to 200 per 100000 pop-
ulation per week.1 Approximately three to ﬁve million
cases of severe inﬂuenza illness and about 250000 to
500000 deaths are estimated from annual epidemics
of inﬂuenza worldwide.2
Inﬂuenza-like illness is frequently complicated with
bacterial superinfection, predominantly Streptococcus
pneumoniae, attributed to a number of factors includ-
ing increased bacterial cell adherence to epithelial lin-
ing and tissue invasion because of damage to
respiratory epithelium and impaired ciliary clearance,
decreased polymorphonuclear and alveolar macro-
phage chemotaxis and suppression of other host im-
mune responses caused by inﬂuenza virus
infection.3,4 A potentially important strategy to reduce
this is to identify modiﬁable risk factors, including
commonly prescribed drugs that inﬂuence ILI
outcomes.
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The benzodiazepines, a class of psychoactive drugs
generally used in the treatment of anxiety and sleep
disorders, have recently been suggested as having det-
rimental effects on immune response to infection, pre-
disposing users to increased risk of infection and
mortality.5 In animal studies, benzodiazepines in-
creased mortality from Klebsiella pneumoniae,6 Strep-
tococcal pneumoniae,5 Mycobacterium bovis7 and
Salmonella typhimurium.8 In addition, mice treated
with diazepam at anxiolytic (non-sedative) doses dur-
ing inﬂuenza alone had an increased burden of sponta-
neous bacterial superinfections in their lungs and
increased mortality from bacterial superinfection of in-
ﬂuenza.5 Treatment of C57BL/6 mice with diazepam
was shown to increase the hazard ratio (HR) of death
from combined inﬂuenza and streptococcal pneumonia
infection (HRs 5.86; 95% conﬁdence interval (CI)
[1.37, 25.10]; p=0.02).5 Mechanistic studies have
shown that diazepam acts via bicarbonate-permeable
gamma-amino butyric type A (GABAA) receptors lo-
cated on immune cells.5,9 Activation of GABAA re-
ceptors leads to cytoplasmic acidiﬁcation in
macrophages, resulting in impaired cytokine produc-
tion, phagocytosis and bacteria killing.5 This delays
the innate immune response leading to subsequent cy-
tokine storm from increased bacterial replication, cul-
minating in increased infection risk and mortality.
Furthermore, the GABAergic system is regulated by
bacterial toll-like receptor signalling indicating an en-
dogenous role in immunity, which is opposed by ad-
ministration of exogenous GABAA modulators such
as benzodiazepines and Z-drugs.10 Importantly, hu-
man and mouse immune cells, including alveolar mac-
rophage, express GABAA receptors,5,9 leading to
translational evidence that humans may be at risk. In
sum, accumulating data from laboratory studies sug-
gest that benzodiazepines impair the host response to
bacterial infection5,11 and hence may increase suscep-
tibility to secondary consequences of inﬂuenza includ-
ing pneumonia and mortality.
Clinical correlates of these preclinical studies have
been reported. In critical care patients, sedation with
the benzodiazepine midazolam was associated with a
doubling of secondary infection compared with the
non-GABAergic dexmedetomidine (19.7 vs 10.2%;
p=0.02).12 Furthermore, sedation with lorazepam,
compared with dexmedetomidine, has been associated
with increased mortality in septic patients.13
In the community, meta-analysis of evidence from
randomised controlled trials of commonly prescribed
Z-drugs (zopiclone, zolpidem, ramelteon and
zaleplon) found increased risk of infection with Z-
drugs compared with placebo (risk ratio 1.44; 95%CI
[1.25, 1.64]).14 In a recent general population study,
benzodiazepine use was associated with increased
pneumonia risk (odds ratio (OR) 1.54; 95%CI [1.42,
1.67]).15 On the other hand, a study in elderly patients
did not ﬁnd a statistically signiﬁcant association be-
tween benzodiazepines and pneumonia (OR 1.08;
95%CI [0.84, 1.47]), although wide CIs were reported,
which may partly be due to low numbers of patients
exposed to benzodiazepines in this study.16 In regard
to mortality risk, evidence from large general popula-
tion studies reports increased mortality with hypnotic
use.15,17,18
Based on the apparent increased susceptibility to
spontaneous bacterial infection5,15,19 and mortality re-
lated to benzodiazepines in the setting of infection,5,6,8
we aimed to investigate these effects in patients with
ILI. We hypothesised that benzodiazepine use would
increase the risk of developing ILI-related pneumonia
and ILI-related death. The same hypothesis was tested
among users of zopiclone, a hypnotic drug that also
acts on GABAA receptors.
METHODS
This study was approved by the Independent Scientiﬁc
Advisory Committee for Medicines and Healthcare
Products Regulatory Agency for database research
(reference number: 11_098R).
Data source
This study used data from the Clinical Practice Re-
search Datalink (CPRD), which contains anonymised
medical records of over 13 million patients prospec-
tively collected from over 600 general practices across
the UK. Given that general practitioners are the gate-
keepers of primary care and specialist referrals in the
UK, CPRD is a rich source of health data for research,
including data on demographics, test, diagnoses, ther-
apies and health-related behaviours. The range of data
available for research is greatly enhanced by linkage of
CPRD with datasets from disease-speciﬁc cohorts,
secondary care and mortality records. This study
utilised CPRD linkages to the Ofﬁce of National Sta-
tistics (ONS) mortality database.
Study design and population
A retrospective cohort study was undertaken to assess
the association between benzodiazepines and ILI-
related pneumonia and ILI-related mortality. This
study included 804337 patients of all ages with a re-
corded diagnosis of ILI within the study period
(2005–2011 (Appendix S1)). These were identiﬁed
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using a deﬁned set of medical Read codes (disease di-
agnostic codes). To be included in the study, patients
were required to be registered with the general practice
for at least 2years. Patient outcomes were ascertained
over a 30-day follow-up period starting at the point
of ILI diagnosis. Patients who developed the outcome
at the start of follow-up (i.e. day of ILI diagnosis or
consultation) were also included in the analysis to
overcome potential biases due to exclusion of delayed
ILI diagnoses or more severe cases.
Outcome deﬁnition
There were two outcomes of interest: (1) ILI-related
pneumonia and (2) ILI-related mortality. ILI-related
pneumonia was deﬁned as clinically diagnosed pneu-
monia occurring within 30days after the diagnosis of
ILI. Data on pneumonia were identiﬁed using relevant
disease diagnostic codes, and the ﬁrst ever eligible
record of pneumonia in the study period was retained
in the analyses.
Deaths occurring within the 30-day follow-up pe-
riod, regardless of cause, were considered as poten-
tially ‘ILI related’. For patients with death records in
both CPRD and ONS mortality data, the date of death
was preferentially determined from ONS data if in
conﬂict. Death data for the remaining subjects were
obtained solely from CPRD records (as ONS mortal-
ity data are available only for subjects registered with
English practices that consent to CPRD–ONS data
linkage). The 30-day window used to deﬁne ILI-
related death is in keeping with the convention used
in previous mortality studies, which treated deaths
within 30days of an event to be event-related
deaths.20
Exposure deﬁnition
Data on all recorded prescriptions of
benzodiazepines/zopiclone for study patients were ex-
tracted from the patient records. Benzodiazepines were
considered both as a class and as individual drugs,
represented by the three most frequently prescribed
benzodiazepines in the study population, namely,
diazepam, temazepam and lorazepam. Exposure was
considered current when the most recent prescription
was within 30days prior to the ILI diagnosis date.
The presence of a repeat prescription was used as a
proxy indicator of long-term drug use, whereas the
absence of it was considered short-term use. Prescrip-
tions in the period of 31–90days and >90days before
ILI diagnosis date were classiﬁed as recent and past
exposures, respectively. No evidence of prescribing
at any point in the patient’s past primary care records
deﬁned ‘non-users’.
Study covariates
A wide range of potential confounders was considered
including depression, anxiety, stress, psychosis, in-
somnia and other sleep disorders (as conditions in
which benzodiazepines/zopiclone may be indicated
and that have been identiﬁed as important confounders
in previous related studies)15,17 and co-morbidity bur-
den measured by Charlson’s co-morbidity index score,
which is a weighted co-morbidity score that is an indi-
cator of the patient’s disease burden.21 The following
co-morbidities are included in the derivation of
Charlson’s co-morbidity index: congestive heart
failure, myocardial infarction, peripheral vascular
disease, dementia, cerebrovascular disease, chronic
pulmonary disease, connective tissue disease, ulcer dis-
ease, liver disease, renal disease, diabetes, hemiplegia,
cancers and AIDS. Table S3 includes the weights
associated with each co-morbidity. Furthermore, cur-
rent prescriptions of opioids, corticosteroids, statins,
antibiotics, antivirals and inﬂuenza vaccination in the
year preceding the diagnosis of ILI were considered.
The absence of a record for the aforementioned covar-
iate in the patient’s primary care record deﬁned the
non-exposure state to the respective covariate. Addi-
tional covariates included were current smoking, alco-
hol consumption, body mass index, gender, age at ILI
diagnosis and Index of Multiple Deprivation (IMD).
IMD data relate to patient residence postcode and are
only available for a subset of English practices
consenting to CPRD data linkage system. Therefore,
not all patients included in the analysis had IMD data,
and a dummy variable category for missing IMD data
was created for the analyses.
Statistical analyses
The Cox proportional hazards regression analysis was
used in both the analyses for ILI-related pneumonia
and ILI-related mortality after checking that the pro-
portional hazards assumption was met. Validity of
the proportional hazards assumption was tested using
log–log plots and the global test for proportional
hazards. Missing data on current smoking, alcohol
consumption, body mass index and IMD were
included in the analysis as dummy variable categories.
Two multivariable models (Models 1 and 2) were con-
structed for each exposure variable. Model 2 included
all a priori confounders, while Model 1 included all
variables that were either
benzodiazepines and ili related pneumonia/mortality
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Table 1. Characteristics of exposed (benzodiazepine users) and unexposed (benzodiazepine non-users) patients (n = 804 051)
Characteristics
Benzodiazepine exposure
p-value*No (n = 743 769) (%) Yes (n = 60 282) (%)
Age (years)
<18 343 128 (46.13) 675 (1.12)
18–44 218 717 (29.41) 21 794 (36.15)
45–65 113 376 (15.24) 23 498 (38.98)
>65 68 548 (9.22) 14 315 (23.75) p trend< 0.001
Gender
Male 326 670 (43.92) 18 455 (30.61)
Female 417 099 (56.08) 41 827 (69.39) <0.001
Index of Multiple Deprivation score in quintiles
1 (least deprived) 100 914 (13.57) 8184 (13.58)
2 96 764 (13.01) 8257 (13.70)
3 77 532 (10.42) 6663 (11.05)
4 89 771 (12.07) 6960 (11.55)
5 (most deprived) 81 874 (11.01) 5962 (9.89) p trend< 0.001
Missing 296 914 (39.92) 24 256 (40.24)
Current smoking
No 240 337 (32.31) 33 048 (54.82)
Yes 67 022 (9.01) 12 593 (20.89) <0.001
Missing 436 410 (58.68) 14 641 (24.29)
Alcohol consumption
≤Alcohol weekly limit 150 076 (20.18) 24 043 (39.88)
>Alcohol weekly limit 14 875 (2.00) 2665 (4.42) <0.001
Missing 578 818 (77.82) 33 574(55.69)
Sleep disorders
No 715 381 (96.18) 52 399 (86.92)
Yes 28 388 (3.82) 7883 (13.08) <0.001
Anxiety
No 737 374 (99.14) 58 282 (96.68)
Yes 6395 (0.86) 2000 (3.32) <0.001
Stress
No 741 232 (99.66) 59 622 (98.91)
Yes 2537 (0.34) 660 (1.09) <0.001
Depression
No 738 895 (99.34) 59 209 (98.22)
Yes 4874 (0.66) 1073 (1.78) <0.001
Psychosis
No 743 683 (99.99) 60 269 (99.98)
Yes 86 (0.01) 13 (0.02) 0.033
Charlson’s co-morbidity index score
0 593 787 (79.83) 35 530 (58.94)
1–2 131 932 (17.74) 19 960 (33.11)
3–5 15 097 (2.03) 3891 (6.45)
>5 2953 (0.40) 901 (1.49) p trend< 0.001
Body mass index
Normal weight 108 723 (14.62) 16 419 (27.24)
Underweight 7436 (1.00) 946 (1.57)
Overweight 79 443 (10.68) 13 870 (23.01)
Obesity 56 079 (7.54) 10 995 (18.24) p trend< 0.001
Missing 492 088 (66.16) 18 052 (29.95)
Corticosteroids
No 736 027 (98.96) 59 499 (98.70)
Yes 7742 (1.04) 783 (1.30) <0.001
Opioids
No 739 100 (99.37) 59 657 (98.96)
Yes 4669 (0.63) 625 (1.04) <0.001
Statins
No 742 569 (99.84) 60 009 (99.55)
Yes 1200 (0.16) 273 (0.45) <0.001
Antivirals
No 738 977 (99.36) 59 975 (99.49)
Yes 4792 (0.64) 307 (0.51) <0.001
Antibiotics
(Continues)
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a signiﬁcantly associated with both ILI-related pneu-
monia or ILI-related mortality and benzodiazepines
(p<0.05) or
b variables that modiﬁed the unadjusted effect of
benzodiazepine on the outcomes of interest by at
least 10%.
Given that benzodiazepines and other GABAergic
drugs are commonly used as hypnotics and anxiolytics
in adults,22,23 we conducted a sensitivity analysis
among study subjects aged 18years and older. We fur-
ther stratiﬁed the analyses of the effects of benzodiaz-
epines on ILI-related pneumonia and death according
to the following age groups: <25, 25–44, 45–64 and
≥65years.
A subgroup analysis was undertaken for the out-
come ILI-related death, to account for severity of
ILI, deﬁned as a diagnosis of pneumonia within
30days following an ILI diagnosis. The sensitivity
analysis for diagnosed inﬂuenza was not possible as
only 5% of ILI cases were inﬂuenza (as identiﬁed by
inﬂuenza Read codes).
All data handling and analysis were performed in
STATA v12 SE (StataCorp, College Station, Texas,
USA). Results are presented as unadjusted and
adjusted HRs, with accompanying 95%CIs.
RESULTS
Patient characteristics
Of the 804337 ILI patients identiﬁed in the study pe-
riod, 804051 were included in the analyses after ex-
clusion of those with anomalous data (Appendix S1).
The median age at ILI diagnosis was 25years
(interquartile range: 4–48years). During the 30days
of follow-up, 1117 (0.14%) patients developed
pneumonia, while 707 (0.09%) died with an overall in-
cidence rate of 4.67 per 100000 person-days and 2.96
per 100000 person-days for ILI-related pneumonia
and death, respectively.
Table 1. (Continued)
Characteristics
Benzodiazepine exposure
p-value*No (n = 743 769) (%) Yes (n = 60 282) (%)
No 743 282 (99.93) 60 234 (99.92)
Yes 487 (0.07) 48 (0.08) 0.195
Inﬂuenza vaccination
No 739 386 (99.41) 59 475 (98.66)
Yes 4383 (0.59) 807 (1.34) <0.001
In bold are statistically signiﬁcant differences (i.e. p< 0.05) between benzodiazepine users and non-users with regard to covariates.
*p-values from chi-squared test.
Figure 1. Inﬂuenza-like illness (ILI)-related pneumonia adjusted cumulative hazard rate during 30 days of follow-up period
benzodiazepines and ili related pneumonia/mortality
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Benzodiazepine and zopiclone use was noted in
60282 (7.5%) and 25578 (3.18%) study patients,
respectively. Study patients prescribed benzodiaze-
pines were more likely to be adults, female, users of
other drugs and have co-morbid diseases as compared
with non-users of benzodiazepines (Table 1).
In the ILI-related pneumonia analyses, covariates
that met the inclusion criteria for Model 1 (as deﬁned
in the previous section) were age, deprivation, current
smoking, alcohol use, sleep disorders, Charlson’s
co-morbidity index score and body mass index. Model
1 in the ILI-related mortality analyses included age,
Charlson’s co-morbidity index score, anxiety, sleeping
disorders, opioids, alcohol consumption, current
smoking, body mass index, statins, antivirals and
inﬂuenza vaccination (Tables 1, S1 and S2).
The association between benzodiazepines/zopiclone
and inﬂuenza-like illness-related pneumonia
The adjusted cumulative hazard rate curves indicate
increased pneumonia risk with benzodiazepine use
(Figure 1). Table 2 presents HRs for the association
between study drugs and occurrence of pneumonia
within 30days following ILI diagnosis. Benzodiaze-
pine use at any time before ILI diagnosis was
Table 2. Association between benzodiazepine/zopiclone use and ILI-related pneumonia in all ages (n = 804 051)
Drug ILI-related pneumonia
Yes (n = 1117)
Unadjusted model
HR [95%CI]
Adjusted model HR [95%CI]
Model 1 Model 2
Benzodiazepines
Non-use 981 (0.13) 1.00 1.00 1.00
Use 136 (0.23) 1.72 [1.43, 2.05] 1.33 [1.10, 1.60] 1.35 [1.12, 1.63]
Benzodiazepines*
Current 10 (0.70) 5.43 [2.91, 10.12] 4.17 [2.23, 7.79] 4.24 [2.27, 7.95]
Recent 6 (0.30) 2.28 [1.02, 5.09] 1.79 [0.80, 4.00] 1.84 [0.82, 4.11]
Past 120 (0.21) 1.60 [1.33, 1.94] 1.24 [1.02, 1.51] 1.26 [1.03, 1.54]
Benzodiazepines duration
Short-term use 124 (0.21) 1.61 [1.34, 1.94] 1.26 [1.04, 1.53] 1.28 [1.05, 1.56]
Long-term use 12 (0.68) 5.21 [2.95, 9.21] 3.10 [1.74, 5.51] 3.14 [1.76, 5.60]
Diazepam
Non-use 1016 (0.13) 1.00 1.00 1.00
Use 101 (0.21) 1.61 [1.31, 1.97] 1.25 [1.01, 1.54] 1.27 [1.03, 1.57]
Diazepam timing*
Current 4 (0.42) 3.17 [1.19, 8.47] 2.46 [0.92, 6.57] 2.52 [0.94, 6.76]
Recent 6 (0.39) 2.95 [1.32, 6.59] 2.36 [1.05, 5.27] 2.43 [1.09, 5.44]
Past 91 (0.20) 1.53 [1.23, 1.89] 1.19 [1.05, 5.27] 1.21 [0.97, 1.51]
Temazepam
Non-use 1065 (0.14) 1.00 1.00 1.00
Use 52 (0.21) 1.56 [1.18, 2.06] 1.09 [0.82, 1.46] 1.11 [0.83, 1.49]
Temazepam timing*
Current 5 (0.97) 7.26 [3.02, 17.48] 5.15 [2.13, 12.45] 5.19 [2.15, 12.57]
Recent 1 (0.16) 1.15 [0.16, 8.14] 0.83 [0.12, 5.89] 0.85 [0.12, 6.05]
Past 46 (4.20) 1.45 [1.08, 1.94] 1.01 [0.75, 1.338] 1.03 [0.76, 1.40]
Lorazepam
Non-use 1105 (0.14) 1.00 1.00 1.00
Use 12 (0.40) 2.95 [1.67, 5.20] 2.02 [1.14, 3.59] 2.08 [1.17, 3.70]
Lorazepam timing†,*
Current 2 (2.47) — —
Recent 0 (0.00) — —
Past 10 (0.36) — —
Zopiclone
Non-use 1063 (0.14) 1.00 1.00 1.00
Use 54 (0.21) 1.55 [1.18, 2.04] 1.16 [0.87, 1.54] 1.18 [0.89, 1.56]
Zopiclone timing*
Current 3 (0.34) 2.56 [0.82, 7.94] 1.95 [0.63, 6.07] 1.97 [0.63, 6.12]
Recent 2 (0.20) 1.49 [0.37, 5.98] 1.13 [0.28, 4.52] 1.16 [0.29, 4.65]
Past 49 (0.21) 1.52 [1.14, 2.02] 1.13 [0.84, 1.52] 1.15 [0.85, 1.55]
ILI, inﬂuenza-like illness; CI, conﬁdence interval; HR, hazard ratio.
Model 1 adjusted for age, sex, Charlson’s co-morbidity index score, insomnia and other sleeping disorders, alcohol consumption, current smoking, body mass
index and Index of Multiple Deprivation; Model 2: Model 1 covariates, sex, anxiety, stress, depression, psychosis, opioids, steroids, statins, antibiotics, anti-
virals and ﬂu vaccination. Statistically signiﬁcant results are highlighted in bold. Drug non-users are the comparison group.
*The reference group is the non-user category of the respective drug.
†The effect of drug timing was not calculated due to insufﬁcient numbers of respective drug use within the categories.
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associated with a 35% increase in the risk of develop-
ing ILI-related pneumonia compared with not using
benzodiazepines (adjusted HR 1.35; 95%CI [1.12,
1.63]). A heightened increase in the occurrence of
ILI-related pneumonia was observed with current
benzodiazepine use (adjusted HR 4.24; 95%CI [2.27,
7.95]). ILI-related pneumonia was observed among
both short-term and long-term users of benzodiaze-
pines (short-term use: adjusted HR 1.28, 95%CI
[1.05, 1.56]; long-term use: adjusted HR 3.14, 95%
CI [1.76, 5.60]). Similar statistically signiﬁcant
increases in ILI-related pneumonia were found within
the assessed individual benzodiazepines (diazepam,
temazepam and lorazepam). The observed increase in
the occurrence of ILI-related pneumonia with
zopiclone use lacked statistical signiﬁcance (adjusted
HR 1.18; 95%CI [0.89, 1.56]).
The association between benzodiazepines/zopiclone
and inﬂuenza-like illness-related mortality
Similar to observations for ILI-related pneumonia, the
adjusted cumulative hazard rate curves for ILI-related
death showed increased death hazard with benzodiaz-
epine use (Figure 2). Benzodiazepine use at any time
prior to ILI diagnosis was associated with a 63% in-
crease in ILI-related death (adjusted HR 1.63; 95%CI
[1.37, 1.93]). The observed effect was strengthened
with an approximately 20-fold increase in mortality
with current use of benzodiazepines (adjusted HR
20.69; 95%CI [15.54, 27.54]). The increase in
30-day mortality was also observed among current
users of individual benzodiazepines as well as
zopiclone (Table 3).
Sensitivity analyses
Low numbers of patients with ILI-related
pneumonia/mortality (outcomes of interest) were
observed across the various exposure categories. For
instance, only 6 and 12 subjects with recent exposure
to benzodiazepines experienced ILI-related pneumo-
nia and ILI-related death, respectively (Tables 2 and
3). Simulation studies suggest that there should be a
minimum number of around 10 outcome events per
variable included in a regression model for statistically
signiﬁcant associations.24,25 To fulﬁl this criteria, cur-
rent and recent categories of benzodiazepine use were
combined, for one of the sensitivity analyses, so that
>10 events would be present per category in the re-
gression model. Cox regression analysis results for
the recoded benzodiazepine use variable (prescription
of benzodiazepines within 90days prior to the
diagnosis of ILI compared with benzodiazepines
non-use) show statistically signiﬁcant increased risk
of ILI-related pneumonia and mortality (ILI-related
pneumonia results: adjusted HR 2.84, 95%CI [1.73,
4.69]; ILI-related mortality results: adjusted HR
10.78, 95%CI [8.30, 14.01]).
Figure 2. Inﬂuenza-like illness (ILI)-related death adjusted cumulative hazard rate during 30 days of follow-up period
benzodiazepines and ili related pneumonia/mortality
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The sensitivity analysis for the association between
any time benzodiazepine use and ILI-related pneumo-
nia among study subjects aged 18years and older
produced HRs similar to the original estimates (sensi-
tivity analysis results: adjusted HR 1.34, 95%CI [1.11,
1.62], p=0.003; original results: adjusted HR 1.35,
95%CI [1.12, 1.63], p=0.002). Likewise, the results
for the sensitivity analysis of ILI-related mortality
were similar to the primary calculations (sensitivity
analysis results: adjusted HR 1.81, 95%CI [1.52,
2.15], p<0.001; original results: adjusted HR 1.98,
95%CI [1.67, 2.36], p<0.001).
Stratiﬁed analyses according to patient age groups
showed increased occurrence of ILI-related death
with exposure to benzodiazepines in most age groups:
<25years (HR 31.50; 95%CI [7.41, 133.84]), 25–
44years (HR 2.87; 95%CI [1.30, 6.35]) and ≥65years
(HR 1.62; 95%CI [1.35, 1.95]). In patients aged be-
tween 45 and 64years, the association between ben-
zodiazepine and ILI-death lacked statistical
signiﬁcance (HR 0.97; 95%CI [0.54, 1.72]). On the
other hand, the increased occurrence of ILI-related
pneumonia with exposure to benzodiazepines was
only observed among patients aged less than 65years
(<25years: HR 2.60, 95%CI [1.31, 5.14]; 25–
44years: HR 1.31, 95%CI [0.93, 1.84]; 45–64years:
HR 1.77, 95%CI [1.26, 2.49]; ≥65years: HR 0.95,
95%CI [0.68, 1.34]).
A subgroup analysis for the ILI-related death outcome
that excluded 1117 patients with severe ILI (patients
Table 3. Association between benzodiazepine/zopiclone use and ILI-related mortality in all ages (n = 804 051)
Drug ILI-related death
Yes (n = 707)
Unadjusted model HR
[95%CI]
Adjusted model HR [95%CI]
Model 1 Model 2
Benzodiazepines
Non-use 521 (0.07) 1.00 1.00 1.00
Use 186 (0.31) 4.42 [3.74, 5.22] 1.60 [1.35, 1.89] 1.63 [1.37, 1.93]
Benzodiazepines
Current 55 (3.84) 57.43 [43.50, 75.83] 20.63 [15.53, 27.42] 20.69 [15.54, 27.54]
Recent 12 (0.60) 8.64 [4.87, 15.31] 3.41 [1.92, 6.06] 3.38 [1.90, 6.01]
Past 119 (0.21) 2.99 [2.45, 3.65] 1.09 [0.89, 1.33] 1.11 [0.91, 1.34]
Benzodiazepines duration
Short-term use 142 (0.24) 3.47 [2.89, 4.18] 1.31 [1.09, 1.58] 1.34 [1.11, 1.61]
Long-term use 44 (2.48) 36.34 [26.72, 49.44] 5.57 [4.07, 7.60] 5.58 [4.09, 7.63]
Diazepam
Non-use 600 (0.08) 1.00 1.00 1.00
Use 107 (0.23) 2.88 [2.34, 3.54] 1.12 [0.91, 1.38] 1.15 [0.93, 1.41]
Diazepam timing
Current 23 (2.41) 31.32 [20.65, 47.51] x11.85 [7.76, 18.08] 12.36 [8.09, 18.90]
Recent 5 (0.33) 4.18 [1.73, 10.09] 1.91 [0.79, 4.61] 1.95 [0.80, 4.71]
Past 79 (0.18) 2.24 [1.77, 2.83] 0.88 [0.69, 1.11] 0.90 [0.71, 1.14]
Temazepam
Non-use 621 (0.08) 1.00 1.00 1.00
Use 86 (0.35) 4.42 [3.53, 5.54] 1.36 [1.08, 1.72] 1.38 [1.09, 1.75]
Temazepam timing
Current 24 (4.64) 61.12 [40.66, 91.90] 20.10 [13.27, 30.42] 19.56 [12.85, 29.78]
Recent 4 (0.62) 7.86 (2.94–21.01) 2.41 (0.90–6.48) 2.30 (0.86–6.20)
Past 58 (0.25) 3.13 [2.39, 4.09] 0.97 [0.73, 1.27] 0.98 [0.75, 1.30]
Lorazepam
Non-use 676 (0.08) 1.00 1.00 1.00
Use 31 (1.05) 12.46 [8.69, 17.85] 3.30 [2.30, 4.75] 3.37 [2.34, 4.85]
Lorazepam timing
Current 9 (11.11) 149.05 [77.21, 287.10] 35.11 [18.12, 68.05] 34.82 [17.95, 67.55]
Recent 7 (6.03) 74.61 [35.43, 157.11] 16.77 [7.93, 35.45] 15.70 [7.39, 33.35]
Past 15 (0.54) 6.43 [3.85, 10.72] 1.72 [1.03, 2.88] 1.76 [1.05, 2.95]
Zopiclone
Non-use 631 (0.08) 1.00 1.00
Use 76 (0.30) 3.68 [2.90, 4.67] 1.46 [1.14, 1.86] 1.48 [1.16, 1.89]
Zopiclone timing
Current 20 (2.28) 29.32 [18.77, 45.76] 10.81 [6.90, 16.93] 10.86 [6.93, 17.02]
Recent 7 (0.71) 8.86 [4.21, 18.67] 3.61 [1.70, 7.63] 3.61 [1.70, 7.64]
Past 49 (0.21) 2.56 [1.91, 3.42] 1.01 [0.75, 1.36] 1.02 [0.76, 1.38]
ILI, inﬂuenza-like illness; CI, conﬁdence interval; HR, hazard ratio.
Drug non-users are the comparison group. Model 1 adjusted for age, Charlson’s co-morbidity index score, anxiety, sleeping disorders, opioids, alcohol con-
sumption, current smoking, body mass index, statins, antivirals and ﬂu vaccination. Model 2 adjusted for all model variables plus sex, stress, depression, psy-
chosis, multiple deprivation, steroids and antibiotics. Statistically signiﬁcant results are highlighted in bold.
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diagnosed with pneumonia within 30days following
ILI) from the main alnalysis model (anytime benzodiaz-
epine use) yielded comparable results with the original
ones (subgroup analysis results: adjusted HR 1.68,
95%CI [1.40, 2.01], p<0.001; original results: adjusted
HR 1.63, 95%CI [1.37, 1.93], p<0.001).
DISCUSSION
Summary of main ﬁndings
Results from this study indicate that benzodiazepine
use is associated with increased occurrence of both
ILI-related pneumonia and mortality. The increased
risk is present with long-term as well as short-term
use of benzodiazepines. This effect is also present
across the individual benzodiazepines assessed,
namely, diazepam, temazepam and lorazepam.
Zopiclone, the non-benzodiazepine hypnotic with the
same mechanism of action as benzodiazepines, was
also found to be associated with increased ILI-related
mortality but not pneumonia.
Strengths and limitations
Given almost all ILI cases are managed in the com-
munity, using general practice data allowed access to
a large sample of ILI patients (n=804051) as well
as to a wide range of data pertaining to patient pre-
scription and medical history. As these were cohort
data, temporal biases relating to timing of exposure
were minimised. This study also adjusted for a wide
range of potential confounders. Confounding by co-
morbidity was controlled for using a robust measure,
Charlson’s co-morbidity index, designed speciﬁcally
to predict mortality given a set of co-morbid dis-
eases.26 This co-morbidity measure has also been val-
idated for use in morbidity studies.27 In addition,
other illnesses identiﬁed in literature as confounders
of the relationship between benzodiazepines and
disease outcomes were controlled for. These include
insomnia and sleep disorders, depression, psychosis,
anxiety and stress.15,17 Furthermore, other drugs that
could be concurrently prescribed with benzodiaze-
pines (e.g. opioids and corticosteroids) and lifestyle
factors (e.g. smoking and alcohol consumption) were
controlled for.
A possible limitation of this study may be an overes-
timation of exposure to study drugs (hence underesti-
mation of drug effect) given prescription data, which
do not guarantee drug compliance, were used to
determine exposure status. While this could lead to
misclassiﬁcation bias, the effects are likely to be non-
differential and at most would bias results towards
the null. Nevertheless, the observed associations still
remained when chronic benzodiazepine use as
indicated by repeat prescriptions was assessed
(Tables 2 and 3).
There is also a validity issue of the analysed
clinically diagnosed pneumonia given the absence
of radiological conﬁrmation. However, chest X
rays, although advised in making a diagnosis of
pneumonia, according to the British Thoracic
Society guidelines, are not necessary for the major-
ity of patients with pneumonia managed in primary
care.28
As in any other observational study that uses
secondary data, some residual confounding is inevita-
ble in our results as a consequence of factors that
might have been inadequately assessed.29 However,
considering the minimal impact of the major con-
founders for which we did control, we think it unlikely
that confounding explains the high secondary infec-
tion rate and mortality that we found associated with
benzodiazepines.
A plausible explanation of our observation may be
derived from the recent reports of the immunomodu-
latory effects of benzodiazepines. Sanders et al. have
shown in laboratory studies that activation of
GABAA receptors located on immune cells impairs
the host innate immune defence mechanisms in a
dose-dependent manner.5,9 The higher point esti-
mates with current exposure to benzodiazepines and
long-term use are consistent with the preclinical data
and add weight to the biological plausibility of our
ﬁndings.9 Furthermore, the preclinical studies show
that the impairments that occur with anxiolytic doses
in mice are consistent with community use of the
drugs.15 All clinically available benzodiazepines are
non-speciﬁc, targeting any Gamma2 subunit-
containing GABAA receptor.30,31 Intriguingly,
Sanders et al. found that anxiolytic doses of benzo-
diazepines that lacked activity at Alpha1-Gamma2-
containing GABAA receptors did not impair immune
responses.5 Our data suggest that alternatives to
non-speciﬁc benzodiazepines should be investigated.
It is possible that more selective drugs could be
developed that would have an improved immune
side effect proﬁle.
Comparison with existing literature
The ﬁndings from the current study are in line with re-
sults from a similar epidemiological study by Obiora
et al.15 This also observed a statistically signiﬁcant
but weaker association between current benzodiaze-
pine use and increased pneumonia-related mortality
benzodiazepines and ili related pneumonia/mortality
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(adjusted HR 1.35). It is interesting to note that the ef-
fect of benzodiazepines on ILI-related pneumonia
lacked statistical signiﬁcance in patients aged
≥65years (HR 0.95; 95%CI [0.68, 1.34]). Such a ﬁnd-
ing however is not unique to our study as previous
pneumonia studies have also failed to establish a
statistically signiﬁcant effect of benzodiazepines on
pneumonia risk among the elderly.32,33 A possible
explanation may be the presence of high co-morbidity
burden in older adults. In a recent study of the impact
of benzodiazepines on asthma outcomes34 and in the
paper of Obiora et al.,15 an interaction with co-
morbidity was observed, with the effect of benzodiaz-
epines being larger in patients with lower co-morbidity
burden. The effect of co-morbidity on the
benzodiazepine-associated change in risk of pneumo-
nia may be explained by the inﬂuence of cumulative
disease processes outweighing the effects of the drug.
Another explanation is that inﬂammation from
co-morbid diseases inﬂuences the expression of the
GABAA receptor, the suggested immune target for
benzodiazepines.5,9 Sanders et al.5 observed that
certain inﬂammatory cytokines and stimuli reduce
GABAA receptor expression on alveolar macrophage.
Thus, a reduction in expression of the receptor target,
by co-morbid inﬂammation, would be expected to
result in a reduction of detrimental effects of benzodi-
azepines on immune response to infection.
The association between benzodiazepine use and in-
creased secondary infection observed in this study is
also supported by ﬁndings from animal and clinical
studies; for instance, treatment with diazepam at anxi-
olytic doses increased susceptibility to streptococcal
pneumonia superinfection in inﬂuenza-infected
C57BL/6 mice.5 Similarly, in critically ill patients, in-
creased risk of secondary infection was reported in se-
dation with benzodiazepine midazolam relative to
dexmedetomidine.19 However, in this latter study,
higher doses of benzodiazepines were used for seda-
tion, thus limiting the generalisability of their ﬁndings
to studies assessing benzodiazepine use in the commu-
nity.15,32 Increased infection risk has also been found
with the use of non-benzodiazepine GABAergic hyp-
notics, including zopiclone, in a meta-analysis of data
from randomised controlled trials.14 Although the cur-
rent study observed an increased occurrence of ILI-
related pneumonia with zopiclone use, this association
failed to achieve statistical signiﬁcance. A possible ex-
planation may be the lack of statistical power as low
numbers of patients were exposed to zopiclone in this
study (Table 2).
Mortality estimates for use of benzodiazepines and
zopiclone at any point in time prior to ILI diagnosis
observed in this study are comparable with ﬁndings
from some previous studies.35–38 However, the present
estimates of current benzodiazepine/zopiclone use are
higher than those reported in the available litera-
ture.17,18 The higher mortality point estimates also
persisted in the sensitivity analysis that combined cur-
rent and recent benzodiazepine exposure into a single
category to boost numbers of exposed patients with
the outcome of interest (ILI-related mortality sensitiv-
ity analysis results: adjusted HR 10.78, 95%CI [8.30,
14.01]; original results: adjusted HR 20.69, 95%CI
[15.54, 27.54]). A plausible explanation for the differ-
ences in mortality estimates observed in the present
study compared with previous studies could be the dif-
ferent study populations utilised. Unlike previous
studies undertaken in the general population,17,18,35
the present study assessed the effects of benzodiaze-
pines in a cohort of patients with underlying ILI diag-
nosis, and results from animal models of infection
have reported increased susceptibility to underlying
infection with benzodiazepine use.5,6
CONCLUSION
This study shows statistically signiﬁcant associations
between benzodiazepine use and increased occurrence
of ILI-related pneumonia and mortality. In light of the
existing evidence, this study adds weight to previously
expressed concerns regarding the safety of benzodiaz-
epines with respect to respiratory infection risk and
mortality.
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KEY POINTS
• An increased likelihood of inﬂuenza-like illness-
related pneumonia and mortality was found with
benzodiazepine use.
• A similar increase in the occurrence of inﬂuenza-like
illness-related deaths was found with zopiclone use.
• These ﬁndings suggest a cautionary approach to
prescribing benzodiazepine in people known to
be at increased risk of pneumonia or mortality.
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